News Releases Keyword Search Year None20232022202120202019201820172016 May-04-2023 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results Apr-27-2023 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results Apr-13-2023 Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors Apr-03-2023 Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 Mar-27-2023 Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Mar-09-2023 Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results Mar-02-2023 Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results Mar-01-2023 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Feb-01-2023 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Jan-04-2023 Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »